Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Income (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Operating Income for 16 consecutive years, with -$710000.0 as the latest value for Q4 2025.

  • Quarterly Operating Income fell 32.96% to -$710000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Dec 2025, down 12.47% year-over-year, with the annual reading at -$2.4 million for FY2025, 12.52% down from the prior year.
  • Operating Income hit -$710000.0 in Q4 2025 for Guided Therapeutics, down from -$485000.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$359000.0 in Q1 2024 to a low of -$1.5 million in Q2 2023.
  • Historically, Operating Income has averaged -$678750.0 across 5 years, with a median of -$592000.0 in 2021.
  • Biggest five-year swings in Operating Income: plummeted 240.08% in 2021 and later soared 57.41% in 2024.
  • Year by year, Operating Income stood at -$435000.0 in 2021, then plummeted by 117.93% to -$948000.0 in 2022, then surged by 48.84% to -$485000.0 in 2023, then dropped by 10.1% to -$534000.0 in 2024, then tumbled by 32.96% to -$710000.0 in 2025.
  • Business Quant data shows Operating Income for GTHP at -$710000.0 in Q4 2025, -$485000.0 in Q3 2025, and -$763000.0 in Q2 2025.